OKYO Pharma (NASDAQ:OKYO) Given Buy Rating at HC Wainwright

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 366.67% from the stock’s previous close.

OKYO Pharma Stock Performance

OKYO stock opened at $1.50 on Monday. OKYO Pharma has a 1 year low of $0.81 and a 1 year high of $1.74. The stock’s fifty day moving average price is $1.32 and its 200-day moving average price is $1.17.

Institutional Investors Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. FNY Investment Advisers LLC bought a new stake in shares of OKYO Pharma Limited (NASDAQ:OKYO) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 20,000 shares of the company’s stock, valued at approximately $25,000. FNY Investment Advisers LLC owned about 0.06% of OKYO Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.